TY - JOUR
T1 - What is the best path towards allogeneic transplantation in MDS and AML?
T2 - A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation
AU - Krause, Stefan W.
AU - Bethge, Wolfgang
AU - Bug, Gesine
AU - Elmaagacli, Ahmet
AU - Jost, Edgar
AU - Klein, Stefan A.
AU - Kobbe, Guido
AU - Kraus, Sabrina
AU - Kruger, William H.
AU - Luft, Thomas
AU - Muller, Lutz P.
AU - Schafer-Eckart, Kerstin
AU - Schetelig, Johannes
AU - Steiner, Normann
AU - Stelljes, Matthias
AU - Tischer, Johanna
AU - Winkler, Julia
AU - Wolff, Daniel
AU - Wortmann, Friederike
AU - Rollig, Christoph
N1 - Schäfer: Department of Internal Medicine 5, Klinikum Nuernberg,
Paracelsus Medizinische Privatuniversität, Nürnberg,
Germany
PY - 2026/6
Y1 - 2026/6
N2 - Allogeneic hematopoetic stem cell transplantation (allo SCT) is a treatment option with a unique chance of cure for patients with high-risk AML or MDS. However, the optimal path for an individual patient on its way to allo SCT is far from clear and subject of ongoing debates. Upfront transplantation "as soon as possible" competes with strategies to achieve deep remission or at least stabilization of the disease. In this context, we performed a survey among German transplant centers to assess their preferred strategies for patients before SCT in five typical scenarios of AML and MDS. We obtained replies from 22 centers, revealing a heterogenous use of possible strategies. Upfront transplantation was a preferred option (68%) in intermediate risk MDS, chemotherapy was preferred (64%) as bridging for AML in remission, whereas hypomethylating agents (HMA) and induction chemotherapy for relapsed AML were highly controversial. Further prospective evaluation of different options is desirable.
AB - Allogeneic hematopoetic stem cell transplantation (allo SCT) is a treatment option with a unique chance of cure for patients with high-risk AML or MDS. However, the optimal path for an individual patient on its way to allo SCT is far from clear and subject of ongoing debates. Upfront transplantation "as soon as possible" competes with strategies to achieve deep remission or at least stabilization of the disease. In this context, we performed a survey among German transplant centers to assess their preferred strategies for patients before SCT in five typical scenarios of AML and MDS. We obtained replies from 22 centers, revealing a heterogenous use of possible strategies. Upfront transplantation was a preferred option (68%) in intermediate risk MDS, chemotherapy was preferred (64%) as bridging for AML in remission, whereas hypomethylating agents (HMA) and induction chemotherapy for relapsed AML were highly controversial. Further prospective evaluation of different options is desirable.
KW - Bridging
KW - Hematopoietic stem cell transplantation
KW - Induction chemotherapy
KW - Standard of care
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pmu_pure&SrcAuth=WosAPI&KeyUT=WOS:001785267600001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1007/s00277-026-07115-9
DO - 10.1007/s00277-026-07115-9
M3 - Original Article
C2 - 42249084
SN - 0939-5555
VL - 105
JO - ANNALS OF HEMATOLOGY
JF - ANNALS OF HEMATOLOGY
IS - 7
M1 - 298
ER -